{
    "nct_id": "NCT03396874",
    "official_title": "Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence",
    "inclusion_criteria": "1. Histopathological proven prostate adenocarcinoma.\n2. Rising prostate specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).\n\n   1. Post radical prostatectomy (RP) - according to American Urological Association (AUA) recommendation criteria: PSA greater than 0.2 ng/mL measured more than 6 weeks after RP and confirmatory persistent PSA greater than 0.2 ng/mL.\n   2. Post-radiation therapy - according to ASTRO-Phoenix consensus definition: Nadir + greater than or equal to 2 ng/mL rise in PSA.\n3. Karnofsky performance status of ≥ 50.\n4. Age ≥ 18.\n5. Ability to understand a written informed consent document, and the willingness to sign it.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Current investigational therapy for prostate cancer.\n2. Unable to lie flat, still or tolerate a PET/CT scan.\n3. Prior history of a malignancy within the last 2 years, except skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized, and except superficial bladder cancer.\n4. Prisoner.",
    "miscellaneous_criteria": ""
}